Last reviewed · How we verify
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg (bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg)
Stimulates the body's immune system to produce antibodies against the SARS-CoV-2 virus.
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, developed by Pfizer, holds a significant market position as one of the leading COVID-19 vaccines, with three approved indications and substantial revenue potential. Its competitive advantage lies in its ability to stimulate a robust immune response, though it faces strong competition from Moderna’s mRNA-1273.222, which demonstrates greater effectiveness in preventing hospitalizations and outpatient visits, especially in older adults. A key risk is the rapid evolution of the SARS-CoV-2 virus, which may reduce the vaccine's efficacy over time, necessitating frequent updates. The pipeline outlook remains promising, with ongoing development of updated formulations like the XBB1.5 containing mRNA vaccines, which aim to maintain consistent dosing and enhance protection against emerging variants.
At a glance
| Generic name | bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg |
|---|---|
| Sponsor | Pfizer |
| Drug class | mRNA vaccine |
| Target | Spike protein |
| Modality | RNA therapeutics |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg is a type of mRNA vaccine that uses a piece of genetic material called messenger RNA to instruct cells in the body to produce a specific protein. This protein, known as the spike protein, is found on the surface of the SARS-CoV-2 virus. When the vaccine is administered, the mRNA is taken up by cells in the body, which then produce the spike protein. The immune system recognizes the spike protein as foreign and mounts an immune response, producing antibodies that can recognize and bind to the protein. This immune response provides protection against future infections with the SARS-CoV-2 virus.
Approved indications
- Prevention of COVID-19 in individuals 12 years of age and older
- Prevention of COVID-19 in individuals 5 years of age and older
- Prevention of COVID-19 in individuals 6 months through 4 years of age
Common side effects
- Headache
- COVID-19
Drug interactions
- Warfarin
- Aspirin
- Pain medications
- Anticoagulants
- Antiplatelets
- Thrombolytics
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Corticosteroids
- Live vaccines
- Immunosuppressants
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: